Uptake of testing for BRCA1/2 mutations in South East Scotland

被引:18
作者
Holloway, Susan M. [1 ]
Bernhard, Birgitta [1 ]
Campbell, Harry [2 ]
Lam, Wayne W. K. [1 ]
机构
[1] Western Gen Hosp, Dept Clin Genet, Edinburgh EH4 2XU, Midlothian, Scotland
[2] Univ Edinburgh, Sch Med, Dept Publ Hlth Sci, Edinburgh, Midlothian, Scotland
关键词
BRCA1; BRCA2; genetic testing; uptake; Scotland;
D O I
10.1038/ejhg.2008.17
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We investigated the uptake of genetic testing by 54 families in South East Scotland with a BRCA1/2 mutation. At a median of 37 months since identification of the mutation, the overall rate of uptake of testing in 269 eligible family members was 32%. First-degree relatives were significantly (P < 0.05) less likely to be referred for genetic counselling in more, compared to less, socioeconomically deprived families (46 versus 68%). Among relatives who attended for genetic counselling, females were more likely to be tested than males (76 versus 53%; P < 0.05) and relatives with children more than those without children (82 versus 53%; P < 0.001). Tested relatives were older than relatives who did not undergo testing (mean 41.9 versus 36.8 years, P < 0.05) but did not differ in degree of relationship to the index case or in socioeconomic deprivation. Our results confirm the findings from other studies of substantially lower rates of uptake of genetic testing for BRCA1/2 mutations than anticipated in earlier predictions. Relatives in more socioeconomically deprived families were less likely to be referred for genetic counselling, which is a matter of concern. This may be partly the result of a lack of understanding of the testing process. Cascading currently does not work in breast cancer families and further work is required to investigate intrafamilial communication patterns, testing behaviour and counselling strategies.
引用
收藏
页码:906 / 912
页数:7
相关论文
共 22 条
[1]   Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer [J].
Armstrong, K ;
Micco, E ;
Carney, A ;
Stopfer, J ;
Putt, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (14) :1729-1736
[2]  
Biesecker BB, 2000, AM J MED GENET, V93, P257, DOI 10.1002/1096-8628(20000814)93:4<257::AID-AJMG1>3.0.CO
[3]  
2-8
[4]  
Bottorff JL, 2002, CANCER EPIDEM BIOMAR, V11, P89
[5]   BRCA1/2 predictive testing:: a study of uptake in two centres [J].
Brooks, L ;
Lennard, F ;
Shenton, A ;
Lalloo, F ;
Ambus, I ;
Ardern-Jones, A ;
Belk, R ;
Kerr, B ;
Craufurd, D ;
Eeles, R ;
Evans, DG .
EUROPEAN JOURNAL OF HUMAN GENETICS, 2004, 12 (08) :654-662
[6]   Non-uptake of predictive genetic testing for BRCA1/2 among relatives of known carriers: Attributes, cancer worry, and barriers to testing in a multicenter clinical cohort [J].
Foster, C ;
Evans, DGR ;
Eeles, R ;
Eccles, D ;
Ashley, S ;
Brooks, L ;
Cole, T ;
Cook, J ;
Davidson, R ;
Gregory, H ;
Mackay, J ;
Morrison, PJ ;
Watson, M .
GENETIC TESTING, 2004, 8 (01) :23-29
[7]  
Gwyn K, 2003, CANCER EPIDEM BIOMAR, V12, P96
[8]   Decision-making about genetic testing among women at familial risk for breast cancer [J].
Jacobsen, PB ;
Valdimarsdottir, HB ;
Brown, KL ;
Offit, K .
PSYCHOSOMATIC MEDICINE, 1997, 59 (05) :459-466
[9]  
Julian-Reynier C, 2000, PSYCHO-ONCOL, V9, P504, DOI 10.1002/1099-1611(200011/12)9:6<504::AID-PON491>3.0.CO
[10]  
2-R